Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways by Pareja, Fresia et al.
ARTICLE OPEN
Phyllodes tumors with and without ﬁbroadenoma-like areas
display distinct genomic features and may evolve through
distinct pathways
Fresia Pareja1, Felipe C. Geyer1, Rahul Kumar1, Pier Selenica1, Salvatore Piscuoglio 1,2, Charlotte K. Y. Ng 1,2,3, Kathleen A. Burke1,
Marcia Edelweiss1, Melissa P. Murray1, Edi Brogi1, Britta Weigelt1 and Jorge S. Reis-Filho1
Breast ﬁbroepithelial lesions (ﬁbroadenomas and phyllodes tumors) are underpinned by recurrent MED12 exon 2 mutations, which
are more common in ﬁbroadenomas and benign phyllodes tumors. TERT promoter hotspot mutations have been documented in
phyllodes tumors, and found to be more frequent in borderline and malignant lesions. Several lines of evidence suggest that a
subset of phyllodes tumors might arise from ﬁbroadenomas. Here we sought to investigate the genetic differences between
phyllodes tumors with ﬁbroadenoma-like areas vs. those without. We retrieved data for 16 borderline/ malignant phyllodes tumors,
including seven phyllodes tumors with ﬁbroadenoma-like areas and nine phyllodes tumors without ﬁbroadenoma-like areas, which
had been previously subjected to targeted capture massively parallel sequencing. Whilst MED12 exon 2 mutations were
signiﬁcantly more frequent in tumors with ﬁbroadenoma-like areas (71 vs. 11%), an enrichment in genetic alterations targeting
bona ﬁde cancer genes was found in those without ﬁbroadenoma-like areas, in particular in EGFR mutations and ampliﬁcations (78
vs. 14%). No signiﬁcant difference in the frequency of TERT genetic alterations was observed (71% in cases with ﬁbroadenoma-like
areas vs 56% in those without ﬁbroadenoma-like areas). Our data suggest that the development of phyllodes tumors might follow
two different evolutionary pathways: a MED12-mutant pathway that involves the progression from a ﬁbroadenoma to a malignant
phyllodes tumor; and a MED12-wild-type pathway, where malignant phyllodes tumors arise de novo through the acquisition of
genetic alterations targeting cancer genes. Additional studies are warranted to conﬁrm our observations and deﬁne whether the
outcome differs between both pathways.
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INTRODUCTION
Fibroadenomas (FA) and phyllodes tumors (PT) are part of the
spectrum of breast ﬁbroepithelial lesions.1 Whilst FAs are benign
tumors of frequent occurrence, which are usually managed
conservatively, PTs are rare and may recur locally or even
metastasize to distant sites.2 PTs are classiﬁed according to criteria
recommended by the World Health Organization (WHO), which
include tumor borders, stromal cellularity and atypia, mitotic
activity and stromal overgrowth, into benign, borderline and
malignant categories.1 Albeit not perfectly, the histologic grading
of PTs is predictive of clinical behavior.1 Recurrence rates reported
in the literature are of 10–17%, 14–25% and 23–30% for benign,
borderline, and malignant PTs, respectively.1 Although metastases
may occur in association to a PT of any grade, they are
signiﬁcantly more frequent following malignant PTs.3–5 PTs are
managed with surgical excision and clear margins, with surgical
margins status being an important predictor of clinical behavior.3
FAs and PTs share not only histologic similarities, but also
genetic features. Highly recurrent and clonal somatic mutations
targeting the exon 2 of MED12 have been identiﬁed in both FAs
and PTs,6–11 suggesting these constitute early founder events.
Additional genes, such as FLNA, SETD2 and RARA, are mutated in
both entities but at a lower frequency in FAs.11 Importantly,
among PTs, a stepwise decrease in the prevalence of MED12
mutations from benign to borderline and to malignant PTs has
been demonstrated.10 Moreover, whilst FAs have a less complex
genomic landscape and lower mutational burden than PTs,11
somatic genetic alterations in bona ﬁde cancer genes, such as NF1,
RB1, TP53, PIK3CA, and EGFR appear to be restricted malignant and
few borderline PTs.10,11 Finally, TERT promoter mutations and gene
ampliﬁcations are absent or exceedingly rare in FAs, but recurrent
in PTs, though signiﬁcantly more frequent in borderline and
malignant PTs than in benign PTs, suggesting that TERT genetic
alterations might play a role in the progression from benign to
malignant PTs.8,10,12,13
Malignant PTs are often histologically heterogeneous, display-
ing areas consistent with benign PTs or even FAs. Some studies
have suggested that FAs may rarely progress to malignant PTs.14–16
Importantly, however, whilst grade progression within PTs is a
well-described phenomenon,17–19 progression from FAs to PTs
remains a matter of contention. Recent analyses of synchronous or
metachronous ipsilateral ﬁbroepithelial lesions revealed identical
MED12 mutations in pairs of FA and PT (benign and malignant),
providing molecular evidence in support of the clonal relatedness
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between FAs and PTs from the same patients.11,20 In one patient
with three FAs, one benign PT and one malignant PT in the same
breast, we found that only the malignant PT, which was clonally
related to one of the three FAs, harbored a TERT promoter
mutation.20 These ﬁndings support the notion that FAs might
constitute the substrate for the development of PTs, and that TERT
genetic alterations might drive malignant progression in ﬁbroe-
pithelial lesions.11,20
Taken together, given that MED12 mutations are signiﬁcantly
more common in benign ﬁbroepithelial lesions than in malignant
PTs, that FAs might constitute the substrate for the development
of a subset of PTs and that TERT genetic alterations might drive
malignant progression in ﬁbroepithelial lesions, we hypothesized
that the development of borderline and malignant PTs might
follow two distinct evolutionary pathways, according to MED12
status. In the MED12-mutant pathway, a linear progression from
FA/ benign PT to borderline/ malignant PT would occur and be
likely driven by the acquisition of TERT genetic alterations. By
contrast, in the MED12-wild type pathway, borderline and
malignant PTs are more likely to develop de novo, and driven
by early genetic alterations in TERT and/or other cancer genes. To
test this hypothesis, we investigated the differences in the
repertoire of somatic genetic alterations of borderline and
malignant PTs with FA-like areas, which might presumably have
stemmed from a pre-existing FA, vs. that of PTs without FA-like
areas, which might have arisen de novo.
RESULTS
Our study cohort consists of 16 PTs, previously described by
Piscuoglio et al.,10 which were categorized by six pathologists with
expertise in breast pathology (FP, FCG, ME, MM, EB, and JSR-F) as
ﬁve borderline PTs and 11 malignant PTs according to WHO
criteria.1 Only cases with all histologic slides available for re-review
were included in this study. The median number of sections
reviewed was 21 (range 8–42). In addition, all histological sections
were re-reviewed by two pathologists (FP and FCG) to assess the
presence of FA-like areas, deﬁned as intracanalicular, pericanali-
cular or myxoid areas of low stromal cellularity, lacking cytologic
atypia and mitotic activity. Discordant cases were reviewed on a
multi-headed microscope together with a third pathologist (JSR-F)
to reach a consensus. Based on the criteria above, seven PTs (ﬁve
borderline and two malignant) were classiﬁed as having FA-like
areas; nine PTs, all of them malignant, had no FA-like areas (Fig. 1).
The number of sections reviewed per case was comparable
between the two groups, (p > 0.05, Mann–Whitney U test).
Fig. 1 Histologic features of phyllodes tumors (PTs) with and without ﬁbroadenoma (FA)-like areas included in this study. Representative
micrographs of a malignant PT with FA-like areas a, displaying areas of marked stromal cellularity and cytologic atypia b intermingled with FA-
like areas showing intracanalicular growth pattern, low stromal cellularity and no cytologic atypia c. Representative micrographs of a
malignant PT without FA-like areas d, displaying inﬁltrative borders, prominent stromal cellularity e, marked cellular atypia and numerous
mitoses f. Scale bars in a and d, 100 μm, b, c, and f, 20 μm, and e, 50 μm
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We ﬁrst compared the two groups (PTs with vs. without FA-like
areas) in regards to their clinico-pathological features. The median
age of the patients with PTs with FA-like areas was 43 years (range
28–55), younger but not signiﬁcantly different from that of
patients with PTs without FA-like areas (median age 58, range
25–76, p > 0.05, Mann–Whitney U test). Likewise, the median size
of the PTs was similar between the group of PTs with FA-like areas,
9 cm (range 1.6–11), and the group of PTs without FA-like areas,
8.5 cm (range 1.6–23, p > 0.05, Mann–Whitney U test). With regard
to the histopathologic features used for the classiﬁcation of PTs
(i.e., stromal cellularity, cytologic atypia, mitotic activity, stromal
overgrowth, heterologous elements, and tumor borders), only
mitotic activity differed signiﬁcantly between the two groups, with
PTs without FA-like areas having more mitoses than PTs with FA-
like areas (p < 0.05, Fisher’s exact test; Table 1).
The massively parallel sequencing data of all cases was
retrieved the NCBI Sequence Read Archive under Accession No.
SRP062618. Brieﬂy, DNA samples from tumor and matching
normal tissue had been subjected to high-depth targeted-capture
massively parallel sequencing using the Memorial Sloan Kettering-
Integrated Mutation Proﬁling of Actionable Cancer Targets (MSK-
IMPACT) platform,21 which interrogates coding regions of up to
410 genes, as well as intronic regions and promoters of selected
genes. MSK-IMPACT sequencing yielded a median depth of
coverage of tumor samples of 556x (range 332x–754x; Supple-
mentary Table 1). No signiﬁcant difference in depth of coverage
was observed between the two groups (p > 0.05, Mann–Whitney U
test). Analysis of the MSK-IMPACT data revealed a similar number
of non-synonymous somatic mutations in the PTs regardless of
the presence of FA-like areas (medians of 4 (range 3–7) and 4
(range 2–8)) in PTs with FA-like areas and PTs without FA-like
areas, respectively (p > 0.05, Mann–Whitney U test; Supplementary
Table 2).
Next we compared the difference in the frequency of mutations
affecting single genes between the two groups. MED12 exon 2
mutations were signiﬁcantly more frequent in PTs with FA-like
areas (5/7, 71%) than in PTs without FA-like areas (1/9, 11%; p <
0.05; Fisher’s exact test; Fig. 2 and Supplementary Table 2). MED12
exon 2 mutations were predicted to be clonal by ABSOLUTE (i.e.
present in virtually 100% of tumor cells analyzed in each sample)
in all PTs with FA-like areas cases (Supplementary Fig. 1). In the
sole MED12-mutant PT without FA-like areas, the MED12 exon 2
mutation was subclonal, suggesting that it might not be the main
genetic driver of this malignant PT at that evolutionary stage
(Supplementary Fig. 1 and Supplementary Table 2). The frequency
of TERT promoter mutations or ampliﬁcations was similar between
the two groups, 5/7 (71%) in PTs with FA-like areas and 5/9 (56%)
in PTs without FA-like areas (p > 0.05, Fisher’s exact test).
Conversely, somatic genetic alterations affecting EGFR, including
ampliﬁcations and likely pathogenic missense mutations, were
signiﬁcantly more frequent in PTs without FA-like areas (7/9, 78%)
than in PTs with FA-like areas (1/7, 14%, p < 0.05, Fisher’s exact
test; Fig. 2). The EGFR mutations targeted the ligand binding and
tyrosine kinase domains, including the G63R, L62R, V774M, and
E84V mutations. Furthermore, somatic genetic alterations in
additional bona ﬁde tumor suppressor genes, such as RB1, TP53,
and NF1, often coupled with loss of heterozygosity of the wild-
type allele, were more frequent in PTs without FA-like areas than
in PTs with FA-like areas (Fig. 2), however these differences did not
reach statistical signiﬁcance. We cannot rule out that the lack of
Fig. 2 Repertoire of somatic genetic alterations identiﬁed in
phyllodes tumors (PTs) with ﬁbroadenoma (FA)-like areas and PTs
without FA-like areas. Heatmap illustrating non-synonymous
somatic mutations, gene ampliﬁcations and homozygous deletions
in PTs with FA-like areas (n= 7) and PTs without FA-like areas (n= 9),
identiﬁed by targeted capture massively parallel sequencing (MSK-
IMPACT). Cases are shown in columns and genes are represented in
rows. Only genetic alterations affecting the 227 genes present in
both targeted capture panels used in this study are shown. The
different genetic alterations are color-coded according to the
legend. Loss of heterozygosity of a mutated gene is indicated by
a diagonal bar. Promoter SNVs are shown with a triangle. MED12
exon 2 mutations are indicated by an asterix; BOPT3 harbored a
MED12 mutation in exon 4. OncoKB level 3A (breast cancer) is
indicated by a circle
Table 1. Histologic features of phyllodes tumors according to the
presence of ﬁbroadenoma-like areas







Tumor border Well deﬁned 4 (57%) 3 (33%) 0.592
Permeative 3 (43%) 6 (67%)
Stromal cellularity Mild 1 (14%) 0 (0%) 0.212
Moderate 4 (57%) 3 (33%)
Marked 2 (29%) 6 (67%)
Stromal atypia Mild 1 (14%) 1 (11%) 0.633
Moderate 5 (71%) 4 (44%)
Marked 1 (14%) 4 (44%)
Mitoses/10 HPF 0–10 6 (86%) 2 (22%) 0.04
>10 1 (14%) 7 (78%)
Stromal
overgrowth
Absent 6 (86%) 5 (56%) 0.308




Absent 7 (100%) 7 (78%) 0.475
Present 0 (0%) 2 (22%)
FA ﬁbroadenoma, PT phyllodes tumor
p-value according to Fisher’s exact test
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signiﬁcant differences in the frequency of mutations affecting
these genes is due to the small number of cases in our cohort.
The sole case of a PT with FA-like areas that was MED12-wild-
type corresponded to a malignant PT associated to a myxoid FA
(Fig. 3). We have previously observed that myxoid FAs, unlike
conventional FAs, do not harbor MED12 exon 2 mutations.22
Importantly, potentially targetable mutations, including the
AKT1 E17K, ERBB2 V777L, ERBB3 V104L, NRAS Q61K, and PIK3CA
H1047R hotspot mutations, were restricted to PTs without FA-like
areas (Fig. 2). Although no clinical evidence is currently available in
terms of their actionability in PTs or sarcomas, clinical data support
the potential targeting of these AKT, ERBB2, and PIK3CA hotspot
mutations in breast cancer (OncoKB level of evidence 3A;23 Fig. 2
and Supplementary Table 3).
DISCUSSION
Even though PTs have been classically regarded as de novo
lesions arising from specialized intra-lobular mammary stroma,
their morphologic and genetic overlap with FAs, the frequent
observation of FA-like areas in a subset of PTs, and the available
molecular evidence demonstrating clonal relatedness between
FAs and PTs in a subset of tumors, suggest that PTs and FAs might
share a common origin.1,11,2,20 Conversely, however, our results
and previous studies10,11,13,8,24 demonstrate that a substantial
proportion of bona ﬁde malignant PTs lack MED12 exon 2
mutations, which are present in the large majority of FAs and
benign PTs. These ﬁndings suggest that MED12-wild-type
malignant PTs may constitute neoplasms distinct from PTs
associated with FAs or that these lesions evolve through distinct
evolutionary paths. Indeed, here we demonstrate that borderline
and malignant PTs with FA-like areas display a signiﬁcantly
different genomic landscape than PTs without FA-like areas. Whilst
PTs with FA-like areas harbor highly recurrent MED12 exon 2
mutations and less common genetic alterations in bona ﬁde
cancer genes, most PTs without FA-like areas are MED12-wild-type
and display more frequent genetic alterations targeting cancer
genes, in particular EGFR (Fig. 2).
Our ﬁndings support the hypothesis that borderline and
malignant PTs may develop following two different evolutionary
pathways. In the setting of the MED12-mutant pathway, borderline
and malignant PTs might stem from a pre-existing FA and
progress to a malignant phenotype following the acquisition of
additional genetic alterations in cancer genes, including TERT
promoter mutations and TERT ampliﬁcation. In the context of the
MED12-independent pathway, malignant PTs might arise de novo
following the early acquisition of genetic alterations affecting
cancer genes, including not only TERT genetic alterations, but,
most strikingly, activation of oncogenes, such as EGFR, and/ or loss
of function of tumor suppressor genes, such as RB1 and TP53
(Fig. 4). Consistent with our genetic ﬁndings, clinical studies have
suggested the existence of two subsets of PTs with different
prognosis depending on a previous history of ipsilateral FA or the
ﬁnding of MED12 somatic mutations.25,26 Abe et al.25 reported that
the overall survival of patients with malignant PTs and a history of
ipsilateral FA was signiﬁcantly longer than the one of patients
without a history of FA. Ng et al.26 observed that PTs harboring
MED12 mutations have a lower recurrence rate than those without
MED12 mutations. Based on these ﬁndings, it could be posited
that PTs with a previous history of FA or with FA-like areas may be
driven by MED12 and associated with a more favorable clinical
outcome, whereas PTs without a history of FA or FA-like areas
develop in a MED12-independent manner and may have a worse
outcome.
It is noteworthy that the single MED12-mutant PT without FA-
like areas harbored a subclonal MED12 mutation, indicating intra-
tumor heterogeneity, whereas in all the other MED12-mutant
cases, the MED12 mutation was clonal and FA-like areas were
present (Fig. 2, Supplementary Fig. 1 and Supplementary Table 2).
This case harbored an EGFR ampliﬁcation, as well as clonal
mutations targeting cancer genes, such as the TP53 R249S and
AKT1 E17K hotspot mutations. Potential explanations include that
a MED12-mutant FA and a MED12-wild type malignant PT
originated independently, and that growth of the latter obliter-
ated the FA areas. Alternatively, the PT might have originated from
a pre-existing FA harboring a MED12 mutation, that was
overgrown by the malignant component driven by EGFR and
AKT1 activation and loss of function of p53, in which MED12
mutation was not required any longer for tumor growth.
Importantly, we have shown that PTs with and without FA-like
areas differ in terms of the somatic genetic alterations that are
potentially targetable, as hotspot mutations in AKT1 (E17K), ERBB2
(V777L), ERBB3 (V104L), NRAS (Q61K), and PIK3CA (H1047R) were
found to be exclusive to PTs without FA-like areas (Fig. 2). Even
though the therapeutic relevance of these ﬁndings in PTs is
currently unknown, clinical evidence supports the role of the
majority of these mutations as predictors of response to speciﬁc
therapeutic agents in other malignancies.27–31 In fact, AZD5363, an
AKT inhibitor has been shown to have therapeutic activity in
breast and ovarian cancer harboring the AKT1 E17K mutation,27
Fig. 3 Histologic features of a phyllodes tumor (PT) with myxoid ﬁbroadenoma (FA)-like areas. Representative micrographs of a malignant PT
with myxoid FA-like areas a, displaying regions with marked stromal atypia and frequent mitoses b immediately adjacent to FA-like areas with
myxoid hypocellular stroma c. Scale bar in a 100 μm, and b and c, 50 μm
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and neratinib, an irreversible dual ERBB2/EGFR tyrosine kinase
inhibitor, has been found to be active in breast cancers with
activating ERBB2 mutations.28
Although there is currently no compelling clinical evidence
supporting the role of EGFR ampliﬁcations and the missense
mutations identiﬁed in this study (i.e., L62R, G63R, E84V, and
V774M) as biomarkers predictive of therapeutic response, these
genetic alterations could be potentially targetable. EGFR ampliﬁ-
cations and the V774M tyrosine kinase mutation are known to be
oncogenic,32 and the L62R, G63R, and E84V mutations have been
recently identiﬁed as new functional variants,33 and target the
ligand domain of EGFR, which plays a crucial role in its
dimerization and activation, and is currently the target of anti-
EGFR monoclonal antibodies such as cetuximab and
panitumumab.34
Our study has important limitations. First, our series did not
include borderline PTs without FA-like areas. However, our
ﬁndings may be a reﬂection of the fact that PTs that stem from
pre-existing FAs might be of lower grade than those developing
de novo. Second, the assessment of the differences in clinical
behavior between PTs with FA-like areas and those without FA-like
areas was not possible due to the small size of our cohort, low
recurrence rate of the lesions and short follow-up time. Third,
sampling of specimens included in the study was performed for
clinical purposes and not tailored for the assessment of the
presence of FA-like areas. Nonetheless, we only included cases for
which all histologic sections were available for re-review. Fourth,
the cases in our study were analyzed using the MSK-IMPACT
platform, which interrogates a limited number of genes; therefore
it is possible that genes not included in this platform (e.g., FLNA)
might be drivers not recognized in our study. Finally, we cannot
exclude the possibility that at least a subset of PTs without FA-like
areas could have originated from a pre-existing FA, in which the
malignant component outgrew and obliterated a pre-existing FA.
Despite the limitations of our study, our data support the notion
that the development of PTs may follow two different evolu-
tionary pathways; a concept that appears to be supported by
histologic features and MED12 mutation status. PTs that may have
stemmed from a pre-existing benign ﬁbroepithelial lesion, such as
a FA, retain FA-like areas and MED12 exon 2 mutations, which
were presumably present in the benign ﬁbroepithelial lesion that
they stemmed from. A different subset of borderline and
malignant PTs might have arisen de novo through the acquisition
of somatic genetic alterations in cancer genes such as EGFR.
Further studies are required to determine whether the different
components of PTs harboring FA-like areas are clonally related, as
well as large longitudinal studies to determine the genetic
alterations responsible for the progression of benign ﬁbroepithe-
lial lesions to borderline and malignant PTs.
METHODS
Cases
Here we performed a reanalysis of the massively parallel sequencing data
of ﬁve borderline PTs and 11 malignant PTs described in our previous
study by Piscuoglio et al.10 The current study focuses on borderline and
malignant PTs with and without FA-like areas. The cases were classiﬁed as
PTs with FA-like areas or PTs without FA-like areas following the re-review
of all cases by six pathologists with expertise in breast pathology. We did
not include the benign PTs from the study by Piscuoglio et al.10 In addition,
one borderline and two malignant PTs from Piscuoglio et al.10 were
excluded from this re-analysis, given that only a subset of the histologic
slides were available for re-review, and, therefore, the presence of FA-like
areas could not be ruled out.
Targeted-capture massively parallel sequencing
A detailed description of tissue microdissection, DNA extraction and
sequencing is provided in the original publication.10 The massively parallel
sequencing data of the relevant cases were retrieved from the NCBI
Sequence Read Archive under Accession No. SRP062618. Tumor and
normal DNA from all borderline PTs and nine malignant PTs had been
analyzed at the Memorial Sloan Kettering Cancer Center Integrated
Genomics Operation (MSKCC IGO) using the MSK-IMPACT sequencing
assay, which interrogates all coding regions and selected intronic regions
and promoters of up to 410 key cancer genes. Detection of somatic
mutations was performed as detailed in Piscuoglio et al.10,35–40 Allele-
speciﬁc copy number alterations were identiﬁed using FACETS.41 Targeted
massively parallel sequencing of cases MaPT19 and MaPT20 had been
performed using MSK-IMPACT v.3, which interrogates all coding exomes
and selected non-coding regions of 275 genes. Detection of somatic
mutations and copy number alterations for these cases had been
performed as described in Cheng et al.21 The 227 genes common to
MSK-IMPACT (410 genes) and MSK-IMPACT v.3 were considered in the re-
analysis described here and are listed in the Supplementary Table 4. The
likelihood of a mutation to be regarded as pathogenic had been assessed
by the integration of the combination of mutation function predictors42–45
and the presence of the mutated gene in the cancer gene lists by Kandoth
et al.46 the Cancer Gene Census47 or Lawrence et al.48 as detailed in
Piscuoglio et al.10 The cancer cell fraction (CCF) of each mutation was
deﬁned using ABSOLUTE (v1.0.6)49,50 as inferred in Piscuoglio et al.10
Mutations were considered clonal if their probability of being clonal was
>50%50 or if the lower bound of the 95% conﬁdence interval of its CCF was
>90%, otherwise the mutations were considered subclonal.
Fig. 4 Proposed model of the evolutionary origin of borderline and malignant phyllodes tumors. Phyllodes tumors might follow two different
evolutionary pathways. (i) In the MED12-mutant pathway, MED12 exon 2 mutations are posited to lead to the development of a benign
ﬁbroepithelial lesion, which upon the occurrence of additional genetic alterations affecting TERT and/ or other cancer genes may progress to a
borderline or malignant phyllodes tumor. (ii) In the MED12-independent pathway, borderline or malignant phyllodes tumors might arise de
novo, through the acquisition of genetic alterations targeting cancer genes, such as TERT and/ or EGFR. TSG tumor suppresor genes
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Statistical analysis
Comparisons of depth of coverage and mutation rates were performed
using the Mann–Whitney U test. Differences in the frequency of genetic
alterations affecting single genes were assessed using Fisher’s exact test.
Two-tailed p-values < 0.05 were considered statistically signiﬁcant.
Data availability
Sequencing data is available at the National Center for Biotechnology
Information Sequence Read Archive under the accession SRP062618. All
relevant data are available from the authors.
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